PDGFRA and non-small cell lung carcinoma: Cediranib developed by AstraZeneca is a potent multikinase inhibitor targeting VEGFR-1/2/3, PDGFRα/β, and c-Kit.186 However, AstraZeneca discontinued the development of cediranib for the treatment of mCRC, NSCLC, and recurrent glioblastoma due to the mediocre results from phase III clinical trials (NCT00399035, NCT00795340, NCT00777153) in these indications.